What does Great Novel Therapeutics Biotech & Medicals do?

Great Novel Therapeutics Biotech & Medicals (7427.TWO) operates in the Biotechnology industry within the Healthcare sector. Full company description, peers, and segment breakdown are on the page above.

What is 7427.TWO's market cap?

Great Novel Therapeutics Biotech & Medicals (7427.TWO) has a market capitalization of approximately $3.96 billion, as of August 26, 2026, based on the most recent share price and shares outstanding.

Does 7427.TWO pay a dividend?

No — Great Novel Therapeutics Biotech & Medicals (7427.TWO) does not currently pay a regular dividend. Many growth-stage companies reinvest earnings into the business instead of returning capital to shareholders. The Dividend tab tracks any future declarations.

Is 7427.TWO profitable?

Great Novel Therapeutics Biotech & Medicals (7427.TWO) currently reports negative earnings on a trailing-twelve-month basis. The Earnings and Financials tabs show the full EPS history, revenue trend, and analyst forecasts for future profitability.

7427.TWO

Great Novel Therapeutics Biotech & Medicals

TWO·Biotechnology · Healthcare

NT$75.30NT$2.00+2.73%

Market capNT$3.96B·Market closed·Aug 26 7:00 AM UTC

Price Chart

NT$75.30+NT$2.00 (+2.73%)today

+112.05%CAGR +16.22%

Select date range

FromTo

Jul 8, 2021Aug 26, 2021 → Aug 26, 2026· 5.0 yrsAug 26, 2026

Key Metrics

7427.TWO does not currently pay a dividend.

EarningsEarnings Tab

EPS (FWD)—

P/E Ratio (FWD)—

EPS Growth (1Y)—

EPS Growth (3Y)—

EPS Growth (5Y)—

Next Earnings Date—

Last Report Date—

Reported vs Estimate—

Earnings Surprise—

FinancialsFinancials Tab

RevenueNT$6.21M

Net Income−NT$111.67M

Net Margin−1,798.7%

Operating Cash Flow−NT$87.92M

Capital ExpendituresNT$49.75M

Free Cash Flow−NT$38.17M

Return on Equity−14.8%

Return on Invested Capital−8.1%

Net CashNT$692.54M

Value Graph

PRO

See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.

Click below to see what's inside, then upgrade to unlock for 7427.TWO and 80,000+ other tickers.

EPS · Price vs. Fair Value Price Fair

Income Statement Flow

PRO

See exactly how 7427.TWO's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.

The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for 7427.TWO and 80,000+ other tickers.

About Great Novel Therapeutics Biotech & Medicals

Great Novel Therapeutics Biotech & Medicals specializes in crafting pharmaceutical solutions to combat advanced and treatment-resistant cancers. Their primary focus lies in the realm of cancer immunotherapy, encompassing the creation of compounds such as tumor microenvironment regulators, epigenetic immunoactivators, and immune-regulating multi-kinase inhibitors. The company was previously known as GNT Biotech & Medicals Corporation. Established in 2013, its headquarters are situated in Taipei City, Taiwan.

CEO: Chia-Nan Chen
Sector: Healthcare
Industry: Biotechnology
Exchange: TWO
Employees: 22
Website: www.gntbm.com.tw

Peers

Peers Tab

4171.TWO

GeneReach Biotechnology Corp.

Cap

NT$994.2M

6827.TWO

MegaPro Biomedical Co., Ltd

Latest News

News Tab

No recent news available.

Frequently Asked Questions About 7427.TWO

What does Great Novel Therapeutics Biotech & Medicals do?: Great Novel Therapeutics Biotech & Medicals (7427.TWO) operates in the Biotechnology industry within the Healthcare sector. Full company description, peers, and segment breakdown are on the page above.
What is 7427.TWO's market cap?: Great Novel Therapeutics Biotech & Medicals (7427.TWO) has a market capitalization of approximately $3.96 billion, as of August 26, 2026, based on the most recent share price and shares outstanding.
Does 7427.TWO pay a dividend?: No — Great Novel Therapeutics Biotech & Medicals (7427.TWO) does not currently pay a regular dividend. Many growth-stage companies reinvest earnings into the business instead of returning capital to shareholders. The Dividend tab tracks any future declarations.
Is 7427.TWO profitable?: Great Novel Therapeutics Biotech & Medicals (7427.TWO) currently reports negative earnings on a trailing-twelve-month basis. The Earnings and Financials tabs show the full EPS history, revenue trend, and analyst forecasts for future profitability.